{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:52:43Z","timestamp":1787849563783,"version":"build-2784847793"},"reference-count":50,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1248\/bpb.b16-00350","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T22:12:17Z","timestamp":1475273537000},"page":"1646-1652","source":"Crossref","is-referenced-by-count":21,"title":["Perturbed Calcineurin-NFAT Signaling Is Associated with the Development of Alzheimer\u2019s Disease"],"prefix":"10.1248","volume":"39","author":[{"given":"Masashi","family":"Asai","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences, Nagasaki University"},{"name":"Graduation School of Biomedical Sciences, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimi","family":"Kinjo","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Kimura","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Mori","sequence":"additional","affiliation":[{"name":"Graduation School of Biomedical Sciences, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kawakubo","sequence":"additional","affiliation":[{"name":"Graduation School of Biomedical Sciences, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiro","family":"Shirotani","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Nagasaki University"},{"name":"Graduation School of Biomedical Sciences, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosuke","family":"Yagishita","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Iwata","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Nagasaki University"},{"name":"Graduation School of Biomedical Sciences, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Avent ND. Maternal plasma biomarkers for Down syndrome: present and future. <i>Drugs Today<\/i>, <b>49<\/b>, 145\u2013152 (2013).","DOI":"10.1358\/dot.2013.49.2.1888610"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Yao Y, Liao Y, Han M, Li SL, Luo J, Zhang B. Two kinds of common prenatal screening tests for Down\u2019s syndrome: a systematic review and meta-analysis. <i>Sci. Rep.<\/i>, <b>6<\/b>, 18866 (2016).","DOI":"10.1038\/srep18866"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Barnhart RC, Connolly B. Aging and Down syndrome: implications for physical therapy. <i>Phys. Ther.<\/i>, <b>87<\/b>, 1399\u20131406 (2007).","DOI":"10.2522\/ptj.20060334"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Bull MJ, Committee on Genetics. Health supervision for children with Down syndrome. <i>Pediatrics<\/i>, <b>128<\/b>, 393\u2013406 (2011).","DOI":"10.1542\/peds.2011-1605"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Kusters MA, Verstegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. <i>Clin. Exp. Immunol.<\/i>, <b>156<\/b>, 189\u2013193 (2009).","DOI":"10.1111\/j.1365-2249.2009.03890.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Gardiner K, Herault Y, Lott IT, Antonarakis SE, Reeves RH, Dierssen M. Down syndrome: from understanding the neurobiology to therapy. <i>J. Neurosci.<\/i>, <b>30<\/b>, 14943\u201314945 (2010).","DOI":"10.1523\/JNEUROSCI.3728-10.2010"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Head E, Silverman W, Patterson D, Lott IT. Aging and Down syndrome. <i>Curr. Gerontol. Geriatr. Res.<\/i>, <b>2012<\/b>, 412536 (2012).","DOI":"10.1155\/2012\/412536"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome. <i>Lancet<\/i>, <b>355<\/b>, 165\u2013169 (2000).","DOI":"10.1016\/S0140-6736(99)05264-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Mancini M, Toker A. NFAT proteins: emerging roles in cancer progression. <i>Nat. Rev. Cancer<\/i>, <b>9<\/b>, 810\u2013820 (2009).","DOI":"10.1038\/nrc2735"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Song G, Li Y, Jiang G. Role of VEGF\/VEGFR in the pathogenesis of leukemias and as treatment targets (Review). <i>Oncol. Rep.<\/i>, <b>28<\/b>, 1935\u20131944 (2012).","DOI":"10.3892\/or.2012.2045"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Macian F. NFAT proteins: key regulators of T-cell development and function. <i>Nat. Rev. Immunol.<\/i>, <b>5<\/b>, 472\u2013484 (2005).","DOI":"10.1038\/nri1632"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Wu H, Peisley A, Graef IA, Crabtree GR. NFAT signaling and the invention of vertebrates. <i>Trends Cell Biol.<\/i>, <b>17<\/b>, 251\u2013260 (2007).","DOI":"10.1016\/j.tcb.2007.04.006"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Arron JR, Winslow MM, Polleri A, Chang CP, Wu H, Gao X, Neilson JR, Chen L, Heit JJ, Kim SK, Yamasaki N, Miyakawa T, Francke U, Graef IA, Crabtree GR. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. <i>Nature<\/i>, <b>441<\/b>, 595\u2013600 (2006).","DOI":"10.1038\/nature04678"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nguyen T, Di Giovanni S. NFAT signaling in neural development and axon growth. <i>Int. J. Dev. Neurosci.<\/i>, <b>26<\/b>, 141\u2013145 (2008).","DOI":"10.1016\/j.ijdevneu.2007.10.004"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain A\u03b2 by neprilysin. <i>Science<\/i>, <b>292<\/b>, 1550\u20131552 (2001).","DOI":"10.1126\/science.1059946"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Iwata N, Sekiguchi M, Hattori Y, Takahashi A, Asai M, Ji B, Higuchi M, Staufenbiel M, Muramatsu S, Saido TC. Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. <i>Sci. Rep.<\/i>, <b>3<\/b>, 1472 (2013).","DOI":"10.1038\/srep01472"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Yanagisawa K, Asami-Odaka A, Suzuki N, Ihara Y. Fractionation of amyloid \u03b2-protein (A\u03b2) in Alzheimer\u2019s disease and Down\u2019s syndrome brains. Presence of membrane-bound A\u03b2. <i>Ann. N. Y. Acad. Sci.<\/i>, <b>786<\/b>, 184\u2013194 (1996).","DOI":"10.1111\/j.1749-6632.1996.tb39061.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Riegel JS, Richie ER, Allison JP. Nuclear events after activation of CD4<sup>+<\/sup>8<sup>+<\/sup> thymocytes. <i>J. Immunol.<\/i>, <b>144<\/b>, 3611\u20133618 (1990).","DOI":"10.4049\/jimmunol.144.9.3611"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Flockhart RJ, Armstrong JL, Reynolds NJ, Lovat PE. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. <i>Br. J. Cancer<\/i>, <b>101<\/b>, 1448\u20131455 (2009).","DOI":"10.1038\/sj.bjc.6605277"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Lange AW, Molkentin JD, Yutzey KE. <i>DSCR1<\/i> gene expression is dependent on NFATc1 during cardiac valve formation and colocalizes with anomalous organ development in trisomy 16 mice. <i>Dev. Biol.<\/i>, <b>266<\/b>, 346\u2013360 (2004).","DOI":"10.1016\/j.ydbio.2003.10.036"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, Olson EN, Bassel-Duby R, Williams RS. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. <i>Circ. Res.<\/i>, <b>87<\/b>, E61\u2013E68 (2000).","DOI":"10.1161\/01.RES.87.12.e61"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Minami T, Horiuchi K, Miura M, Abid MR, Takabe W, Noguchi N, Kohro T, Ge X, Aburatani H, Hamakubo T, Kodama T, Aird WC. Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. <i>J. Biol. Chem.<\/i>, <b>279<\/b>, 50537\u201350554 (2004).","DOI":"10.1074\/jbc.M406454200"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Yao YG, Duh EJ. VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis? <i>Biochem. Biophys. Res. Commun.<\/i>, <b>321<\/b>, 648\u2013656 (2004).","DOI":"10.1016\/j.bbrc.2004.06.176"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Findeis MA. The role of amyloid \u03b2 peptide 42 in Alzheimer\u2019s disease. <i>Pharmacol. Ther.<\/i>, <b>116<\/b>, 266\u2013286 (2007).","DOI":"10.1016\/j.pharmthera.2007.06.006"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) M\u00fcller MR, Rao A. NFAT, immunity and cancer: a transcription factor comes of age. <i>Nat. Rev. Immunol.<\/i>, <b>10<\/b>, 645\u2013656 (2010).","DOI":"10.1038\/nri2818"},{"key":"26","unstructured":"26) Abdul HM, Furman JL, Sama MA, Mathis DM, Norris CM. The NFATs and Alzheimer\u2019s disease. <i>Mol. Cell Pharmacol.<\/i>, <b>2<\/b>, 7\u201314 (2010)."},{"key":"27","unstructured":"27) Reese LC, Taglialatela G. Neuroimmunomodulation by calcineurin in aging and Alzheimer\u2019s disease. <i>Aging Dis.<\/i>, <b>1<\/b>, 245\u2013253 (2010)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Reese LC, Taglialatela G. A role for calcineurin in Alzheimer\u2019s disease. <i>Curr. Neuropharmacol.<\/i>, <b>9<\/b>, 685\u2013692 (2011).","DOI":"10.2174\/157015911798376316"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, McKeon F, Bobo T, Franke TF, Reed JC. Ca<sup>2+<\/sup>-induced apoptosis through calcineurin dephosphorylation of BAD. <i>Science<\/i>, <b>284<\/b>, 339\u2013343 (1999).","DOI":"10.1126\/science.284.5412.339"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Lieberman DN, Mody I. Regulation of NMDA channel function by endogenous Ca<sup>2+<\/sup>-dependent phosphatase. <i>Nature<\/i>, <b>369<\/b>, 235\u2013239 (1994).","DOI":"10.1038\/369235a0"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Kim Y, Lee YI, Seo M, Kim SY, Lee JE, Youn HD, Kim YS, Juhnn YS. Calcineurin dephosphorylates glycogen synthase kinase-3 beta at serine-9 in neuroblast-derived cells. <i>J. Neurochem.<\/i>, <b>111<\/b>, 344\u2013354 (2009).","DOI":"10.1111\/j.1471-4159.2009.06318.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Wei Q, Holzer M, Brueckner MK, Liu Y, Arendt T. Dephosphorylation of tau protein by calcineurin triturated into neural living cells. <i>Cell. Mol. Neurobiol.<\/i>, <b>22<\/b>, 13\u201324 (2002).","DOI":"10.1023\/A:1015385527187"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Cho HJ, Jin SM, Youn HD, Huh K, Mook-Jung I. Disrupted intracellular calcium regulates BACE1 gene expression <i>via<\/i> nuclear factor of activated T cells 1 (NFAT 1) signaling. <i>Aging Cell<\/i>, <b>7<\/b>, 137\u2013147 (2008).","DOI":"10.1111\/j.1474-9726.2007.00360.x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Mei Z, Yan P, Tan X, Zheng S, Situ B. Transcriptional regulation of BACE1 by NFAT3 leads to enhanced amyloidogenic processing. <i>Neurochem. Res.<\/i>, <b>40<\/b>, 829\u2013836 (2015).","DOI":"10.1007\/s11064-015-1533-1"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Carvalho LD, Teixeira LK, Carrossini N, Caldeira AT, Ansel KM, Rao A, Viola JP. The NFAT1 transcription factor is a repressor of cyclin A2 gene expression. <i>Cell Cycle<\/i>, <b>6<\/b>, 1789\u20131795 (2007).","DOI":"10.4161\/cc.6.14.4473"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Liu H, Jin X, Yin X, Jin N, Liu F, Qian W. PKA-CREB signaling suppresses tau transcription. <i>J. Alzheimer\u2019s Dis.<\/i>, <b>46<\/b>, 239\u2013248 (2015).","DOI":"10.3233\/JAD-142610"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Bito H, Deisseroth K, Tsien RW. CREB phosphorylation and dephosphorylation: a Ca<sup>2+<\/sup>- and stimulus duration-dependent switch for hippocampal gene expression. <i>Cell<\/i>, <b>87<\/b>, 1203\u20131214 (1996).","DOI":"10.1016\/S0092-8674(00)81816-4"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Oyama F, Cairns NJ, Shimada H, Oyama R, Titani K, Ihara Y. Down\u2019s syndrome: up-regulation of beta-amyloid protein precursor and tau mRNAs and their defective coordination. <i>J. Neurochem.<\/i>, <b>62<\/b>, 1062\u20131066 (1994).","DOI":"10.1046\/j.1471-4159.1994.62031062.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Karch CM, Jeng AT, Goate AM. Calcium phosphatase calcineurin influences tau metabolism. <i>Neurobiol. Aging<\/i>, <b>34<\/b>, 374\u2013386 (2013).","DOI":"10.1016\/j.neurobiolaging.2012.05.003"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to \u03b2-amyloid-induced neurotoxicity. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>99<\/b>, 6364\u20136369 (2002).","DOI":"10.1073\/pnas.092136199"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Adams SJ, Crook RJ, Deture M, Randle SJ, Innes AE, Yu XZ, Lin WL, Dugger BN, McBride M, Hutton M, Dickson DW, McGowan E. Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration. <i>Am. J. Pathol.<\/i>, <b>175<\/b>, 1598\u20131609 (2009).","DOI":"10.2353\/ajpath.2009.090462"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Dickey CA, Ash P, Klosak N, Lee WC, Petrucelli L, Hutton M, Eckman CB. Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. <i>Mol. Neurodegener.<\/i>, <b>1<\/b>, 6 (2006).","DOI":"10.1186\/1750-1326-1-6"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Liu F, Gong CX. Tau exon 10 alternative splicing and tauopathies. <i>Mol. Neurodegener.<\/i>, <b>3<\/b>, 8 (2008).","DOI":"10.1186\/1750-1326-3-8"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Sun X, Wu Y, Chen B, Zhang Z, Zhou W, Tong Y, Yuan J, Xia K, Gronemeyer H, Flavell RA, Song W. Regulator of calcineurin 1 (RCAN1) facilitates neuronal apoptosis through caspase-3 activation. <i>J. Biol. Chem.<\/i>, <b>286<\/b>, 9049\u20139062 (2011).","DOI":"10.1074\/jbc.M110.177519"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Porta S, Serra SA, Huch M, Valverde MA, Llorens F, Estivill X, Arbon\u00e9s ML, Mart\u00ed E. <i>RCAN1<\/i> (<i>DSCR1<\/i>) increases neuronal susceptibility to oxidative stress: a potential pathogenic process in neurodegeneration. <i>Hum. Mol. Genet.<\/i>, <b>16<\/b>, 1039\u20131050 (2007).","DOI":"10.1093\/hmg\/ddm049"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Mattson MP. Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer\u2019s disease. <i>J. Neurovirol.<\/i>, <b>8<\/b>, 539\u2013550 (2002).","DOI":"10.1080\/13550280290100978"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Ermak G, Pritchard MA, Dronjak S, Niu B, Do Davies KJ. RCAN1 proteins link chronic stress with neurodegeneration? <i>FASEB J.<\/i>, <b>25<\/b>, 3306\u20133311 (2011).","DOI":"10.1096\/fj.11-185728"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Morales-Corraliza J, Mazzella MJ, Berger JD, Diaz NS, Choi JH, Levy E, Matsuoka Y, Planel E, Mathews PM. <i>In vivo<\/i> turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the \u03b2-amyloid depositing mice. <i>PLoS ONE<\/i>, <b>4<\/b>, e7134 (2009).","DOI":"10.1371\/journal.pone.0007134"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Hama E, Shirotani K, Iwata N, Saido TC. Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid \u03b2 peptide clearance in primary neurons. <i>J. Biol. Chem.<\/i>, <b>279<\/b>, 30259\u201330264 (2004).","DOI":"10.1074\/jbc.M401891200"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Nalivaeva NN, Belyaev ND, Zhuravin IA, Turner AJ. The Alzheimer\u2019s amyloid-degrading peptidase, neprilysin: can we control it? <i>Int. J. Alzheimer\u2019s Dis.<\/i>, <b>2012<\/b>, 383796 (2012).","DOI":"10.1155\/2012\/383796"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/10\/39_b16-00350\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T08:59:18Z","timestamp":1692521958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/10\/39_b16-00350\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b16-00350","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}